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Chapter 1
Introduction
1.1

Background

Our internal organs (or, more precisely, organ systems) do not operate in isolation from
one another. Consequently, dysfunction in one organ system often affects others, sometimes
exacerbating the original dysfunction. For instance, pneumonia (an infection of the respiratory system) can result in insufficient oxygen to the kidneys, reducing their ability to
5

filter wastes from the blood, and resulting in abnormally high levels of waste in the blood
[9, 17, 41, 28]. This, in turn, can affect both cardiac and respiratory function, leading to an
even lower oxygen supply for the kidneys, so kidney function is further compromised, and
the patient rapidly declines from an unseen negative feedback loop operating inside them
[10, 25]. In the medical community, this is known as sequential organ failure (SOF), and
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this can arise from trauma, serious infection (leading to sepsis), or in a “regular” illness,
when comorbidities (i.e. pre-existing health conditions) are present [31]. In intensive care
units (ICUs), healthcare professionals routinely use scoring systems like the Sequential Organ
Failure Assessment (SOFA) to predict the likelihood of death in a patient with SOF [22].
It is not an exaggeration to describe the human circulatory (i.e. cardiovascular) system as

1
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the body’s main transport system. This system, consisting of the heart and all blood vessels,
is the main physical interconnection between the main organ systems, as it carries nutrients
and wastes from one organ to another, linking these systems into a single complex network.
Dr. Lester Caudill’s research lab is actively engaged in developing a mathematical model of
this organ system network, with the long-term goal of investigating treatment options (via
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model simulations) for medical conditions (especially pneumonia and sepsis [11]) that lead
to SOF.
Logically, a model of this network should begin with the circulatory system as its foundation. At its core, an acceptable (for our purposes) mathematical model of the circulatory
system must meet certain design criteria:
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• reflect the key functionality of the system (e.g. beating heart, pressure-driven blood
circulation).
• include the ability of our system model to transport nutrients and wastes through the
system (including a second organ system) via blood flow dynamics.
• be mathematically simple enough to be expandable to include models of other organ
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systems.
This research focuses on developing a circulatory system differential equations model that
meets these design criteria.
This thesis is organized as follows: Chapter 1 provides the physiological background of the
circulatory system and its function, which will serve as a basis for our model. We develop and
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present our model in Chapter 2. In Chapter 3, we conduct some model validation via several
numerical proof-of-concept demonstrations. Chapter 4 presents a strategy for modeling
the transport of substances via our model’s “blood,” as well as a potential application to
the evaluation of anti-hypertensive treatments. We conclude our work, and this thesis, in
Chapter 5.
2
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1.2

Previous Models

Over the years, various approaches to modeling the circulatory system have been published. The assumptions of these models and their respective goals vary greatly, influencing
both their potential applications and their limitations. Although our model applies very
similar physiological principles, we seek to simulate more macro-level effects.
45

Arthur C. Guyton is one of the most prominent and early figures to publish circulatory
system modeling research. He determined that previous models had not incorporated all of
the long-term regulation mechanisms, including the relationship between body fluid volumes
and systemic function through a negative feedback loop [16]. For example, an increase
in arterial pressure is balanced out by a decrease in body fluid volume and venous return.
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Guyton focused his studies on exploring the relationship between hypertension and the renal
system [15], but he did not closely examine organ-organ dynamics. In the future, we hope
to provide mathematical modeling insight on this.
In the Neal & Bassingthwaighte 2007 model, baroreceptor control was included to account for time-independent cardiac elastance [29]. The model was implemented to predict
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hemodynamic responses from acute hemorrhage while validating the outcomes with pig hemorrhage experiments. It most notably differs from our model by the inclusion of baroreceptor
control, coronary circulation, nonlinear resistances for systemic circulation, and ventricular
elastance. However, both of our models share the expression of pressure as a function of the
difference of total blood volume and unstressed volume.

60

Albanese et al. 2016 model incorporates an in-depth simulation of pulmonary capillary
blood and alveolar air exchange along with central nervous system regulation mechanisms
[2]. While the flow rate functions resemble the functions that we use, they additionally
incorporate tissue gas exchange flow rates for the major organ systems. They arrange these
organs as parallel circuits; we plan to use a similar method once we are ready to add the

3
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major organ systems.
Ursino & Magosso 2000 assume that the atria have passive compliance and the beating
mechanism of the heart creates active ventricular compliance [46]. This decision prompted
us to consider the atria as insignificant compared to the thick walls and muscular strength
of the ventricles. For our model, the atria do not contract alongside the ventricles.

70

While previous models incorporate complex mechanisms of long-term regulation and
establish many nonlinear relationships, we seek to present a more simplified system. Since
the circulatory system will be a part of a network of inter-connected organs at a later time,
a more simplistic model makes the overall organ systems model more manageable.

1.3
75

Key Cardiac Functionality

The circulatory system relies on a predictable cyclic repetition of beating ventricles to
pump blood to the rest of the body. Cardiac cycle, which is one complete period of a
heartbeat, is approximately 0.8 seconds long with a rate of 75 beats per minute (bpm) [20].
The normal cardiac output is around 4-7 L/min [27]. The heart contains four flow-control
valves connected to the ventricles. They include the mitral and tricuspid valves, known
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together as the atrioventricular (AV) valves, and the aortic and pulmonary valves, known
together as the semilunar (SL) valves (Figure 2.1). The mitral valve regulates flow from the
left atrium to the left ventricle, the tricuspid valve regulates flow from the right atrium to
the right ventricle, the aortic valve regulates flow from the left ventricle to the aorta, and
the pulmonary valve regulates flow from the right ventricle to the pulmonary artery [20].
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Along with the ventricles, the valves operate on their own schedule. The SL valves are
open for roughly 0.21 seconds and the AV valves are open for 0.46 seconds during a single
cardiac cycle [27]. The opening of the valves is driven by blood pressure gradients between
the ventricle and the blood vessel that the valve is located between. There are also two

4

special cases for when both sets of valves are closed. During isovolumetric contraction,
90

the ventricles contract and ventricular pressure rises for the SL valves to open. During
isovolumetric relaxation, the ventricles relax and ventricular pressure decreases for the AV
valves to open. In both scenarios, ventricular blood volume is unchanged from the closure
of the valves.
The ventricles eject blood directly following isovolumetric contraction.
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This blood,

termed stroke volume (SV), is defined as the volume of ejected blood that enters the target
artery per beat. It is often associated with the rapid discharge of blood into the aorta. The
mathematical formula is given by the difference between ventricular end-diastolic volume
(VEDV) and end-systolic volume (VESV). A UK sudy found the following normal reference
ranges for women: LVEDV = 124 mL, LVESV = 49 mL, RVEDV = 130 mL, and RVESV
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= 55 mL. For men, LVEDV = 166 mL, LVESV = 69 mL, RVEDV = 182 mL, and RVESV
= 85 mL [34]. ”L” stands for left and ”R” stands for right.
The Frank-Starling Law is another important concept, particularly governing the idea
that both ventricles output the same stroke volume. Since both sides of the heart contract
almost simultaneously, cardiac output must be fairly equivalent on both sides of the heart

105

to ensure that blood is not pooling up in the lungs [12]. The length of the cardiac muscle
fibers is not the only determinant of ejection force though [7]. Stroke volume is directly
related to preload and afterload. If central venous pressure increases (preload), then the
pressure gradient will drive an increase in blood into the ventricle. The increase in volume
of blood will stretch the muscular fibers of the myocardium and the heart will contract

110

with greater force, releasing more blood into the aorta. Similarly, greater aortic pressure
(afterload) decreases the pressure gradient and limits the blood flow out of the ventricle [48].
The next section further elaborates on the role of pressure gradients and other hemodynamic
parameters in mediating blood flow between any two blood vessels.

5

1.4
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Introduction to Hemodynamics

With numerous fluid dynamic principles available, scientists and mathematicians have
creatively translated these laws for blood flow in the circulatory system. Jean Leonard
Marie Poiseuille performed scientific experiments to identify the relationship, now known
as Poiseuille’s Law, between length L, viscosity µ, diameter D, the flow rate Q of fluids
through the tube, and the pressure gradient ∆P . Equation (1.1) shows a common derivation

120

of Poiseuille’s Law [42].

Q=

πD4 ∆P
128µL

(1.1)

Poiseuille’s Law exhibits how the direction and magnitude of blood flow is dependent on
the pressure exerted in the current location and the pressure exerted in the intended location.
In broad terms, flow rate Q is a function of resistance of a tube R and the difference ∆P
between the pressures entering the tube and leaving the tube. This proportional relationship
125

has been shown to hold in even the the thinnest compartments in the circulatory system,
the capillaries. The Hagen-Poiseuille Law in Equation (1.2) captures flow between two blood
vessels [7].
∆P
R

Q=

(1.2)

Volume of blood and blood pressure are proportional to each other through a quantity
known as compliance. Homer Warner [47] may have been the first cardiologist to explain that
130

average ventricular compliance values change from systolic to diastolic phase. Compliance
can be thought of as the general ”stretchiness” of a blood vessel or ventricle and its ability
to accommodate increasing volumes of blood. The general relationship between compliance,
pressure, and volume is defined in Equation (1.3).

C=

∆V
∆P

6

(1.3)

Blood vessels that have a high compliance are able to accommodate increasing blood
135

volume without exerting much pressure. On average, venous compliance is 30 times greater
than arterial compliance [18]. It is essential to maintain a high venous compliance since
the veins carry a large percentage of the total blood volume, and increased venous stiffness
can lead to adverse cardiovascular events such as hypertension [32]. Compliance eventually
decreases as we age and the walls of the blood vessels become hardened.

140

The equations introduced in this section serve as the framework of our circulatory system
model, and they will be referenced as we introduce our complementary equations.

7

Chapter 2
The Model
2.1
145

Compartment Diagram and Variables

Our circulatory system model includes the four-chambered heart, major blood vessels,
lungs, and a generic organ as a placeholder for systemic organs. The model compartments
and relevant blood flows are represented with a compartment diagram (Figure 2.1). In order
to simplify the structure of the circulatory system, arterial and venous blood vessels are
grouped into single compartments. These compartments only include the larger vessels with

150

higher blood pressure, such as the aorta, large arteries, and proximal pulmonary arteries. The
smaller arterioles and capillaries are included in the lung and generic organ compartments,
where blood pulsation effects greatly diminish from the distribution of blood through these
delicate and highly resistant tubes. This structure allows for the arteries compartment to
reflect aortic blood pressure, the most common metric used by doctors.

155

The left atrium and right atrium, which contract slightly before their ventricular counterparts, are placed with the pulmonary veins and systemic veins. Since researchers appear
to use central venous pressure or atrial pressure as the preload mechanism of stroke volume,
it is presumed that the atria have similar parameters as the venous system [29], [7].

8

Figure 2.1: Compartment diagram for the proposed circulatory system model. For every
adjacent pair of compartments i and j, there is a fate function fij that governs the blood
flow from i to j.

In our model, time is the independent variable and the 8 dependent variables depict the
160

blood volume in each of the 8 compartments. Additionally, we include blood pressure as an
intermediate variable to reflect the relationship between volume and pressure (Table 2.1).
Change in blood volume

dBi
dt

for a compartment i is the difference of the flow rate in and

the flow rate out (Equations (2.1) - (2.8)). With the differential equations now constructed
as a difference in flow rates, our next task is to specify the mathematical forms for the rate
165

functions fij .

9

dBrv
= f81 − f12
dt
dBpa
= f12 − f23
dt
dBL
= f23 − f34
dt
dBpv
= f34 − f45
dt
dBlv
= f45 − f56
dt
dBa
= f56 − f67
dt
dBorg
= f67 − f78
dt
dBv
= f78 − f81
dt

(2.1)
(2.2)
(2.3)
(2.4)
(2.5)
(2.6)
(2.7)
(2.8)

Symbol
t

Description
time

Units
min

Bi

total blood volume
in compartment i

mL

V̄i

blood volume
capacity for
compartment i
blood pressure in
compartment i
compliance for
compartment i

mL

Pi
Ci

mmHg
mL
mmHg

Role
independent
variable
dependent variable

onstant parameter
for non-ventricle
compartments
auxiliary variable
constant parameter
for non-ventricle
compartments

Table 2.1: Key model components along with their descriptions.

10

2.2

Rate Functions

Our choice of rate functions is based, in part, on the following assumptions regarding
back-flow of blood and flow of blood through the organs.
170

Assumptions
1. Back-flow of blood resulting from a negative pressure gradient is impossible.
2. Every flow rate is dependent on a blood pressure gradient.
3. Since valves open and close according to the shift in the blood pressure gradient, heart
valves do not explicitly need to be represented by a variable.
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Each flow rate function can therefore be equated to the Hagen-Poiseuille Law (Equation
(1.2)), where the rate constant kij =

1
.
Rij

(
k12 ∗ (Prv − Ppa )
f12 =
0
(
k23 ∗ (Ppa − PL )
f23 =
0
(
k34 ∗ (PL − Ppv )
f34 =
0
(
k45 ∗ (Ppv − Plv )
f45 =
0
(
k56 ∗ (Plv − Pa )
f56 =
0
(
k67 ∗ (Pa − Porg )
f67 =
0
(
k78 ∗ (Porg − Pv )
f78 =
0
(
k81 ∗ (Pv − Prv )
f81 =
0
11

if Prv > Ppa
if otherwise

(2.9)

if Ppa > PL
if otherwise

(2.10)

if PL > Ppv
if otherwise

(2.11)

if Ppv > Plv
if otherwise

(2.12)

if Plv > Pa
if otherwise

(2.13)

if Pa > Porg
if otherwise

(2.14)

if Porg > Pv
if otherwise

(2.15)

if Pv > Prv
if otherwise

(2.16)

The piecewise function ensures that there is no back flow if the pressure gradient is less
than zero. As an example, blood will not flow in the forward or reverse direction between
the right ventricle and pulmonary arteries if Prv 6> Ppa (Equation (2.9)).
180

Although blood flow is driven by pressure gradients, we want to use blood volume as our
dependent variable. The expected conservation of total blood volume across all compartments of the model makes it easier to prove the validity of the model. In order to convert
between blood pressure and blood volume measures, we also need the rate functions to be
in terms of blood volume.

185

2.3

Pressure/Volume Relationships

The following assumptions are made regarding the pressure/volume relationship for each
compartment.
Assumptions
1. Every compartment, except for the ventricles, has constant compliance and volume
190

capacity. Although the pressure/volume relationship can take on a nonlinear form at
volumes very far from the unstressed volume, the relationship is fairly linear under
normal conditions [14, 29]. Furthermore, it is during times of venoconstriction and
venodilation that compliance will shift. This model disregards these mechanisms as
short-term responses to regulate blood flow with the assumption that our patient is

195

not experiencing adverse cardiovascular events.
2. Ventricular compliance and volume capacity are highest during diastole and lowest
during systole. During diastole, the pressure stays steady as blood is flowing into the
relaxed ventricles. This increase in surface area directly corresponds to the increase
in volume capacity. During systole, the ventricles contract and shrink, resulting in a

200

significant build-up of pressure.
12

3. If the total blood volume within a compartment is only made up of unstressed volume
(V̄ ), then the corresponding pressure is calibrated to zero. Unstressed volume does not
contribute to a change in transmural pressure [2].
Equations (2.17) - (2.24) display the pressures Pi of each compartment in terms of volume
205

capacity V̄i , total blood volume Bi , and compliance Ci . Note that these equations were
derived from Equation (1.3). Pressure is written as a function of change in volume (Brv − V̄rv )
over compliance.

(
Prv =

Brv −V̄rv (t)
Crv (t)

if Brv > V̄rv (t)

0
(

if otherwise

Ppa =

Bpa −V̄pa
Cpa

0
(

0
(

Ppv =
(
Plv =

Bpv −V̄pv
Cpv

if Bpv > V̄pv

0

if otherwise
if Blv > V̄lv (t)

0
(

if otherwise
Ba −V̄a
Ca

0

(

Pv =

if BL > V̄L
if otherwise

Blv −V̄lv (t)
Clv (t)

Pa =
Porg =

if otherwise

BL −V̄L
CL

PL =

if Bpa > V̄pa

Borg −V̄org
Corg

0
(

if Ba > V̄a
if otherwise
if Borg > V̄org
if otherwise

Bv −V̄v
Cv

0

if Bv > V̄v
if otherwise

(2.17)
(2.18)
(2.19)
(2.20)
(2.21)
(2.22)
(2.23)
(2.24)

Modeling nonlinear ventricular compliance or its inversely related counterpart, elastance,
is not entirely novel. In one model, a linear piecewise function for elastance was used to match
210

the pulsating shape of ventricular pressure [8]. In our model, sine functions for ventricular
compliance and volume capacity are fit to the cardiac cycle and the ventricular blood volume
13

graph. Using sine functions instead of linear functions as the non-constant pieces of these
equations makes certain that it is differentiable at each point in the cardiac cycle.
The parameters of the sine functions are defined (Equations (2.25) - (2.28)). Parameters
215

a, b, and c are characteristics of the timing of the cycle: a represents the time that the systolic
period begins, b is the time at which peak pressure is reached during the systolic period,
and c is the time that the systolic period ends. f and s are determined by the frequency of
the beats and the center of the pressure/volume curves, while m and a are the mean values
and the amplitude of the sine curve. mx must be equal to m in order for the constant piece

220

to intersect perfectly with the sine piece at time c. As a result, both m and mx are the
maximum volume capacity values. Figure 2.2 shows the simultaneous fluctuations in volume
capacity and compliance from our model.



m1 − a1 ∗ sin(f 1 ∗ (T − s1))
V̄lv (t) = m2 − a2 ∗ sin(f 2 ∗ (T − s2))


mx1


m3 − a3 ∗ sin(f 1 ∗ (T − s1))
V̄rv (t) = m4 − a4 ∗ sin(f 2 ∗ (T − s2))


mx2

if a ≤ T ≤ b
if b < T ≤ c
if otherwise

(2.25)

if a ≤ T ≤ b
if b < T ≤ c
if otherwise

(2.26)



m5 − a5 ∗ sin(f 1 ∗ (T − s1))
Clv (t) = m6 − a6 ∗ sin(f 2 ∗ (T − s2))


mx3


m7 − a7 ∗ sin(f 1 ∗ (T − s1))
Crv (t) = m8 − a8 ∗ sin(f 2 ∗ (T − s2))


mx4

if a ≤ T ≤ b
if b < T ≤ c
if otherwise

(2.27)

if a ≤ T ≤ b
if b < T ≤ c
if otherwise

(2.28)

14

Figure 2.2: Plot of left ventricular unstressed volume and compliance using the above
piece-wise functions.

So, our final model consists of differential equations (DE) (2.1) - (2.8), with each fij
given by Equations (2.9) - (2.16) and each Pk given by Equations (2.17) - (2.24). With the
225

complete set of equations defined, the differential equations can be solved.

2.4

Model Analysis

A Mathematica notebook was set up with the model equations and parameter values.
Each compartment has a differential equation within the NDSolve[] function that gives a
solution for total blood volume B as a function of time t (Equations (2.1) - (2.8)). Initial
230

conditions for blood volume for each compartment and a time range are required as a part
of this Initial Value Problem (IVP). Initial conditions are based on average values for total
blood volume (Table 2.2).
Blood pressure is also a valuable variable to use when comparing outcomes of the IVP
since we can change between blood volume and blood pressure by Equation (2.17) - (2.24).
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Consequently, blood pressure plots change in response to changing the IVP parameters and
solution.

15

2.5

Choosing the Parameters

In total, there are 41 parameters (excluding the initial conditions). They are made up of
compliances and volume capacities, ventricular compliances and volume capacities, and rate
240

constants. Chapter 3 briefly discusses difficulties in confidently selecting a set of parameter
values to emulate normal hemodynamic circumstances. There is generally a lack of human
hemodynamic data for compliance, volume capacity, and resistance. Many models have
relied on animal experimentation and then scale their results by weight, but this translation
might be oversimplified.
Blood
Pressure
(mmHg)
Right
Ventricle
Pulmonary
Arteries
Lungs
Pulmonary
Veins
Left
Ventricle
Arteries

Generic
Organ
Veins

5-25 [36]
8-20 [19]
14
[Estimated]
8-12
[Estimated]
15-120 [36]
80-120 [13]

60
[Estimated]
8-12 [40]

Total
Blood
Volume
(mL)
EDV:176
[29]
235 [45]

Volume
Capacity
(mL)
53.5-103 [29]
123 [45]

Compliance
Resistance


mL
)
( mmHg∗min
mL
mmHg
1.89-29.15
[29]
6.560 [45]

106 [29]

29.4 [29]

297 [45]

120 [45]

9.12
[Estimated]
25.37 [45]

EDV:126
[29]
1011 [45]

23.7-71.8
[29]
611 [45]

0.19-10.18
[29]
4 [45]

256 [29]

71 [29]

3455 [45]

2900 [45]

5.77
[Esimated]
111.111 [45]

0.0002517
[29]
0.00098784
[29]
0.00076419
[29]
0.00000995
[29]
0.00013479
[29]
0.00700427
[29]
0.00825423
[29]
0.00138447
[29]

Table 2.2: Set of hemodynamic values that play a crucial role in choosing model
parameters. Values are from previous reputable mathematical models, animal experiments,
or estimated based on what appears to create a good fit.
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For arteries and veins, parameter values are calculated from many smaller categories
provided by math models (Table 2.2). Resistances are summed, compliances are averaged,
and total blood volume and capacity are summed in order to calculate values for the larger
compartments in our model. Volumes are summed in order to conserve total blood volume
across the system. Since the chain of these blood vessels can be treated as a series circuit,

250

resistances are summed [29]. Note that the rate constant kij values are calculated as

1
R

since

they are inversely proportional. The generic organ provided the most flexibility in setting
parameter values because it is not associated with one specific systemic organ. Theoretically,
every organ would have unique parameter values and varying blood flow rates across the
capillaries and tissue. This assumption will be considered as we append the organ systems
255

to our model in the future.
Equations (2.29) - (2.49) list the left and right ventricular volume capacity and compliance
parameters. We consider a cardiac period of 0.8 seconds, or

17

1
75

of a minute.

m1 = m2 = 71.8
a1 = a2 = 48.1
mx1 = 71.8
m3 = m4 = 103
a3 = a4 = 49.5
mx2 = 103
m5 = m6 = 10.8
a5 = a6 = 10.61
mx3 = 10.8
m7 = m8 = 29.15
a7 = a8 = 27.26
mx4 = 29.15
450π
2π
f1 =
∗
4
4/3 ∗ cardiac period
3
s1 =
∗ 1/2 of cardiac period
450
2π
450π
∗
f2 =
2
2/3 ∗ cardiac period
4
∗ 2/3 of cardiac period
s2 =
450
3
a=
∗ 1/2 of cardiac period
450
4
b=
∗ 5/6 of cardiac period
450
1
c=
∗ cardiac period
75
T = t − n[t] ∗ c(used to create a repeating cycle)
 
t
−1
n[t] =
c

(2.29)
(2.30)
(2.31)
(2.32)
(2.33)
(2.34)
(2.35)
(2.36)
(2.37)
(2.38)
(2.39)
(2.40)
(2.41)
(2.42)
(2.43)
(2.44)
(2.45)
(2.46)
(2.47)
(2.48)
(2.49)

The literature values in Table 2.2 serve as the basis of our model parameters and provide
necessary context as we judge the results of our model tests.

18
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Chapter 3
Simulations and Tests
Our goal is test our model to make sure that the results are consistent with what is already
known about normal circulatory system function. The plots from Section 3.2, 3.3, and 3.4
are from running simulations on our model; they ultimately demonstrate that our model

265

results are consistent with the literature and our model appears to uphold the principles of
hemodynamics.

3.1

Assumptions

In order to determine parameter values and run purposeful simulations, a hypothetical
healthy patient is considered with the following assumptions.
270

Assumptions
1. The patient is a young and healthy 70 kg male that has normal hemodynamic measures.
Aortic pressure should be in the 80-120 mmHg range and stroke volumes should be
normal.
2. The patient is not undergoing any hemodynamic stress where they would be losing

275

blood. Although each blood vessel with experience fluctuations in blood volume, the
19

patient’s total blood volume will remain constant.

3.2

Validating Blood Pressure and Valves

Since there is a lot of information regarding normal blood pressure ranges for the ventricles
and major blood vessels, we investigate the changing blood pressures for the pulmonary
280

system with the right ventricle and systemic system with the left ventricle.
Every blood vessel downstream of the right ventricle is expected to consistently have
a lower blood pressure than its predecessor (Figure 3.1). The same trend occurs for the
systemic vessels downstream of the left ventricle (Figure 3.2).
We can further look into the functioning of the valves from these figures. Early on

285

during systole, the right ventricular pressure rises above pulmonary arterial pressure and the
pulmonary valve opens. After the ventricle contracts and pressure decreases, pressure falls
below the pulmonary arteries and the pulmonary valve will close. The same holds true for
the left ventricular pressure and aortic pressure due to the aortic valve. In addition, it is
observed that the right ventricular pressure falls within 5 - 30 mmHg and left ventricular

290

pressure ranges from 10-115 mmHg, closely matching the literature. However, the aortic
pressure is only 80 - 105 mmHg, resulting in a need for better parameter values to increase
the amplitude of the aortic pressure curve.

20

Figure 3.1: Plot of blood pressure for the right ventricles Prv , pulmonary arteries Ppa , lungs
PL , and pulmonary veins Ppv for a single cardiac cycle.

Figure 3.2: Plot of blood pressure for the left ventricles Plv , arteries Pa , generic organ Porg ,
and veins Pv for a single cardiac cycle.
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3.3

Validating Total Blood Volume

From the previously stated assumptions, each compartment is expected to display stable
295

solutions for total blood volume and the sum of these blood volumes will remain constant.
Figure 3.3 shows that all pulmonary blood vessels and the right ventricle reach equilibrium
volume after approximately 0.12 minutes. While all of vessels experience short bursts of
changing volumes, the volumes appear to have a steady-state equilibrium.
The left ventricle and systemic system plot shows solutions that are stable from the
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very beginning (Figure 3.4). Although the the graph appears to show less cyclic changes
in volumes across the systemic vessels, the graph is highly skewed by the large volume of
the veins. By creating an additional function for the sum of the blood volume in all of the
compartments, we can confirm that the amount of blood circulating in the whole system is
constant.

Figure 3.3: Plot of blood volume for the right ventricles Brv , pulmonary arteries Bpa , lungs
BL , and pulmonary veins Bpv .

22

Figure 3.4: Plot of blood volume for the left ventricles Blv , arteries Ba , generic organ Borg ,
and veins Bv .
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3.4

Validating Stroke Volume

Now, we determine if the left and right ventricles are ejecting the expected amount of
blood each cardiac cycle. Figure 3.5 reveals that the right ventricle has RV EDV = 170 and
RV ESV = 100 mL for stable cardiac cycles. Then RV SV = 70 mL. While the RV EDV
is very close to the value mentioned in Table 2.2, the RV SV is 15 mL lower than another
310

source [34]. Since stroke volume is individualistic, we conclude that 70 mL falls within a
wide range of normal values.
Figure 3.6 indicates that the left ventricle has roughly LV EDV = 120 and LV ESV = 45
mL after stabilizing. As a result, LV SV = 75 mL. The LV EDV is very close to the value
given in Table 2.2, but the values do fall short from another source [34]. Again, we assume
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that 75 mL falls with a large normal range for left ventricular stroke volume. In addition,
the close equality between LV SV and RV SV preserves the Frank-Starling Law from Section
1.3.
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In conclusion, both ventricles eject the expected amount of blood into the pulmonary
arteries and aorta.

Figure 3.5: Plot of blood volume of the right ventricle Brv for three cardiac cycles.

Figure 3.6: Plot of blood volume of the left ventricle Blv for three cardiac cycles.
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Now that our model has been proven to accurately simulate blood flow in the circulatory
24

system, we can move forward with assessing our model’s ability to transfer oxygen, drugs,
and other vital substances.
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Chapter 4
Two Extensions: Oxygen and
325

Hypertension
These two extensions describe how our current model could be modified to include the
transfer of oxygen and the delivery of drugs. Future directions for these applications are
explained in the context of our subsequent goal to create a major organ systems model.

4.1
330

Oxygen Delivery and Consumption

Oxygen is an essential reactant for various functions on the cellular level, including aerobic cellular respiration. Oxygen molecules are bound to haemoglobin found in erythrocytes
(red blood cells), which are distributed across the body following uptake [5]. Oxygen concentrations can change based on the binding affinity to haemoglobin and successful uptake of
oxygen by the alveoli, so blood flow alone does not dictate oxygen delivery rates. Equation
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(4.1) gives oxygen delivery DO2 in terms of flow rate Q and concentration of arterial oxygen
CaO2 [35].
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DO2 = Q ∗ CaO2

(4.1)

Concentration of arterial oxygen CaO2 is dependent on concentration of hemoglobin, saturation of arterial oxygen, and partial pressure of arterial oxygen. Oxygen consumption
relies on the difference in oxygen content in the arteries and veins connected to the organ.
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Thus, venous oxygen concentration (CvO2 ) is an additional parameter necessary to calculate
the concentration gradient across the organ. Equations (4.2) - (4.6) show how VO2 can be
written as a proportion of DO2 through substitution [6].

VO2 = Q ∗ (CaO2 − CvO2 )
VO2 = DO2 − (Q ∗ CvO2 )
DO2 ∗ CvO2
VO2 = DO2 −
CaO2
CvO2
)
VO2 = DO2 ∗ (1 −
CaO2
CaO2 − CvO2
VO2 = DO2 ∗
CaO2
CaO2 −CvO2
CaO2

(4.2)
(4.3)
(4.4)
(4.5)
(4.6)

can be referenced as the extraction ratio E, the fraction of blood that is taken

up by the tissue (Equation (4.7)).
VO2 = DO2 ∗ E
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(4.7)

Every organ has unique values for regional flow rate, oxygen delivery rate, extraction
ratio, and consumption. These major differences stem from the unique arteries (i.e. renal
artery for the kidneys and the hepatic artery for the liver) that are connected to the organs.
The difference in circuitry of the organ systems allows for local regulation of blood flow. An
increase in extraction ratio could allow for an organ to maintain constant oxygen consumption
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during periods of below-normal delivery rates. In fact, this mechanism happens during
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intense exercise [37]. The heart, skeletal muscle, and brain have the highest extraction
ratios. The brain can only survive for 3 minutes without an adequate amount of oxygen
available [26].
The critical DO2 represents the oxygen delivery rate for which lower rates have a linear
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relationship with oxygen consumption [6]. For values above DO2 , the extraction ratio or blood
flow is adjusted to maintain a constant consumption rate. The heart is the only major organ
known to display a completely dependent relationship between oxygen consumption and
delivery [37]. While the exact pathology of blood flow regulation is unknown, vasodilation
and vasoconstriction are believed to alter the surface area of the arteries and thus adjust
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blood flow rates. However, we are limited by our uncertainty in how the body distributes
oxygen among the vital organs in very extreme hypoxic events [37].
Once our model can successfully simulate oxygen transport dynamics, we can use the
same modeling mechanisms to simulate the transport other important substances (e.g. nutrients, waste products, medications) throughout the body. These mechanisms will crucial
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for modeling sequential organ failure and sepsis.

4.2

Evaluation of Hypertension Medications

Hypertension is a condition of elevated blood pressure and antihypertensive medications
are commonly prescribed to treat chronic and acute hypertension [3]. The drugs are classified
according to their target receptor. Diuretics, renin-angiotensin system inhibitors, calcium
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channel blockers, and beta-blockers are the most common classes of antihypertensives [49].
In broad terms, diuretics work to inhibit sodium, chloride, and/or potassium absorption
or reabsorption [30]. As a result, blood volume and cardiac output decrease [49]. Beta blockers (BB) block the beta-1 adrenergic receptors, which is activated by the neurotransmitter
norepinephrine. Since norepinephrine is critical for stimulating the heart, the blockage re-
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sults in decreased heart rate, contraction, and ultimately lower cardiac output and blood
pressure [30].
Calcium channel blockers (CBB) block the entry of of calcium ions into the smooth blood
vessel walls. The net-effect is a decline in force of contraction of these blood vessels, known
as vasodilation [30]. Calcium channel blockers can either act on only the arteries or arteries
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and cardiac muscles. The renin-angiotensin system (RAS) is composed of multiple pathways
and provides the opportunity for different target inhibitors. There are ACE inhibitors,
angiontension rececptor blockers, and renin inhibitors [30]. Since angiontensin II leads to
increased sodium and water retention and vasoconstriction, inhibitory mechanisms will limit
these responses and decrease blood pressure [30].
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Most of these drugs are only available for oral administration, but clonidine, a centrally
acting agonist, became the first antihypertensive drug available as a patch [39]. Transdermal delivery has some clear advantages; lack of first-pass metabolism and decreased dose
frequency improve patient compliance and limit gastrointestinal (GI) side effects [24]. The
oral and patch versions of clonidine have been shown to display similar efficacy, but the
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patch is associated with more side effects (dry mouth, drowsiness, etc.) [39].
Other than the characterization of hypertension in a patient and the properties of the
available drugs, genetics and preexisting conditions influence drug response and any adverse
reactions. For example, a kidney disease patient will be recommended to take an ACE
inhibitor and an angiotensin receptor blocker while patients experiencing heart failure or
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heart attacks will be told to avoid CCBs [30]. If a patient is not responding to a single class,
combination therapy is usually administered, with CCBs, BBs, and alpha blockers being the
most common combination [21].
In addition to their unique mechanisms of action (MOA), antihypertensive drugs possess
different pharmacokinetic and pharmacodynamic parameters.
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4.3

Modeling Pharmacokinetics

Pharmacokinetics is the science of the absorption, distribution, metabolism, and excretion
of a drug in the body [4]. Some models include the GI system as a compartment [1],
while other models elect to focus on distribution of the drug to the different organs [4].
First-pass metabolism, which is drug metabolism that occurs (due to interactions in the
405

stomach and liver) prior to entering the systemic circulation, is a major disadvantage of
drugs taken orally [4]. First-pass metabolism greatly influences the bioavailability, which is
the proportion of drug that enters the bloodstream. For transdermal drugs, proportion of
drug that successfully passes through the dermis and epidermis layers is dependent on the
lipid solubility property of the drug [4].
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Figure 4.1 shows a compartment diagram for pharmacokinetics of a drug taken orally.
This compartment diagram does not apply to other delivery systems, such as transdermal
patches, because it includes the GI system as the uptake location prior to entering the
bloodstream. We were inspired by [1] to include the GI system as a compartment in order
to best demonstrate differences between drugs given their unique bioavailability properties.
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Many other models [1], [4] do not include a rate of administration g01 , but in our case, we
need it to schedule the administration of multiple doses.
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Figure 4.1: Compartment diagram for pharmacokinetics of oral delivery of drugs. g01 is the
administration rate, g10 is the rate of which the drug is metabolized by the GI system and
turned inactive, g12 is the rate of absorption into the bloodstream, and g20 is the rate of
elimination. The kidneys usually excrete water-soluble drug metabolites.

Again, we set up our differential equations for each compartment given the flow rates
in and out (Equation (4.8) - (4.9)). Amount of drug A is the dependent variable measured
for the GI compartment and concentration of the drug C is the dependent variable for BL
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compartment. Volume of distribution V D is used to convert amount (mg) to concentration
(mg/mL) (Equation (4.9)). It represents the volume of a fluid that a drug would need to
be dissolved in to have the same plasma concentration [4]. V D is a characteristic of a drug
that can be often be found on the FDA or drug manufacturer’s website.

dAGI
= g01 − g12 − g10
dt
dCBL
g12
=
− g20
dt
VD

(4.8)
(4.9)

In Equation (4.10), d is the dose amount (mg) and dt is the time it takes for the drug to
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dissolve in the stomach and become available for absorption into the bloodstream. Equation
(4.11) takes the single dose rate A(t) and schedules multiple doses based on the frequency
of the dose df . The GI will metabolize the (1 − f ) proportion of drug prior to it entering
the bloodstream, where f is the bioavailability fraction.
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(
A(t) =

g01 =

dn
X

d
dt

0

0 ≤ t ≤ dt
if otherwise

(4.10)

A(t)(t − (j − 1) ∗ df )

(4.11)

j=1

g10 = (1 − f ) ∗ k10 ∗ AGI
g12 = k12 ∗ f ∗ AGI
g20 = k20 ∗ CBL

(4.12)
(4.13)
(4.14)

Table 4.1 lists common pharmacokinetic parameters of a drug that are traditionally
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discovered during pre-clinical and clinical trials. Half-life is the amount of time for plasma
concentration to decrease by 50%, tmax is the time it takes for maximum plasma concentration
to be reached, Cmax is the maximum plasma concentration, and steady-state concentration
is the equilibrium concentration reached after multiple doses.

Dose (mg)
Volume of Distribution
(mL)
Half-life (hrs)
tmax (hrs)
Cmax (ng/mL)
Bioavailability (%)
Steady-state Concentration
(ng/mL)

Clonidine tablets
(Catapres)
0.1 (twice a day) [38]
197000 [44]

Clonidine patch
(Catapres)
5 (weekly) [44]
197000 [44]

12-16 [43]
1-3 [43]
0.2-2 [43]
70 [43]
0.30-0.35 [23]

12-16 [44]
within 3 days [33]
N/A
60 [44]
0.8 [33]

Table 4.1: Pharmacokinetic parameters for comparison of oral and transdermal delivery
systems of clonidine provided by the brand Catapres.

Each compartment has a differential equation within the NDSolve[] function that solves
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for either amount of drug or drug concentration. Plasma concentration curves are graphed
separately for oral and transdermal clonidine drugs.
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Figure 4.2: Plot of plasma concentration curve (ng/mL) over time (hours) for a 0.1 mg pill
of Catapres given every 10 hours.

Figure 4.3: Plot of plasma concentration curve (ng/mL) over time (hours) for a 5 mg patch
of Catapres replaced every week.

While the clonidine patch does not undergo first-pass metabolism, a bioavailability less
than 100% indicates that some portion of the drug is lost before absorption. This is most
likely due to the lipid solubility characteristic of the drug and inability for the drug to
440

penetrate the skin and move across the dermis and epidermis layers. We determine that the
skin can act as the GI compartment presented in Figure 4.1 for transdermal drugs.
Figure 4.3 shows a higher maximum plasma concentration and steady-state concentration for the clonidine patch than the clonidine pill in Figure 4.2. Since the pill is also
more frequently administered than the patch, a patient will experience more acute fluctua33
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tions in plasma concentration and potentially varying pharmacological effects. Both plasma
concentration curves show equilibrium concentrations that meet the expected steady-state
concentrations (Table 4.1).

4.4

Modeling Pharmacodynamics

Pharmacodynamics is the study of how a drug interacts with its target receptor to create
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pharmacological effects [4]. For hypertension, the expected response would be a significant
decrease in blood pressure. Dose-response curves measure the effect of a drug given the dose.
Since we do not want to compare dosages, but rather the long-term effects of each drug, it
would be necessary to have a concentration-response curve for each drug of interest. We
would want to evaluate the decrease in blood pressure given the plasma concentration of the
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drug in the body. With this information, we can determine the percent change in parameter
values that are directly affected by a drug given its MOA. In our model, relevant parameter
values are compliance, resistance, and frequency of heart beats (given by the ventricular sine
functions).
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Chapter 5
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Conclusions
While our circulatory system model would benefit from more precise parameter values,
the simulations in Chapter 3 display several parallels with known physiology. Our model
successfully uses the ventricles to pump blood across the blood vessels, lungs, and an organ
for multiple cardiac cycles. We can hypothesize that this model will be able to pump blood
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to multiple organs that are connected in a parallel circuit. A new compartment would be
added for the addition of each major organ system, and new rate functions that connect
the organs to their local arteries and veins would be necessary. As mentioned in Chapter 4,
these regional flow rates dictate delivery of oxygen and it is crucial for each organ’s ability
to regulate regional blood flow.
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We conclude that this model can serve as the framework of a multiple organ system
model to simulate septic infections and sequential organ failure. It could also be worthwhile to further explore the effect of antihypertensive medications with more organ systems
represented. Since the GI system metabolizes drugs and the renal system excretes most
water-soluble drugs and plays a crucial role in the pathology of hypertension [15], the liver
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and kidneys would be important additions for drug delivery models. The oral and transdermal pharmacokinetics model could be valuable later on as we integrate treatment options

35

for cardiovascular conditions and organ damage.
In conclusion, our proposed circulatory system model shows great promise as a foundation
for a major organ systems model to examine the net effects of organ dysfunction.
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